Advances in pharmacological research for retinopathy of prematurity.
10.3724/zdxbyxb-2024-0216
- Author:
Yanxi XIE
1
;
Suilian ZHENG
2
;
Hui YANG
3
,
4
Author Information
1. Department of Ophthalmology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China. 1374199290@qq.com.
2. Department of Ophthalmology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China. doctorlily@foxmail.com.
3. Department of Ophthalmology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China. wzfeyyh@
4. com.
- Publication Type:English Abstract
- Keywords:
Drug;
Notch;
Oxidative stress;
Retinopathy of prematurity;
Review;
Tumor necrosis factor-α;
Vascular endothelial growth factor
- MeSH:
Retinopathy of Prematurity/metabolism*;
Humans;
Signal Transduction/drug effects*;
Infant, Newborn;
Vascular Endothelial Growth Factor A/metabolism*;
Hypoxia-Inducible Factor 1, alpha Subunit/metabolism*;
Tumor Necrosis Factor-alpha/metabolism*;
Oxidative Stress/drug effects*;
Fatty Acids, Omega-3/therapeutic use*;
Phosphatidylinositol 3-Kinases/metabolism*;
Proto-Oncogene Proteins c-akt/metabolism*;
Receptors, Notch/metabolism*;
Angiogenesis Inhibitors/therapeutic use*;
Insulin-Like Growth Factor I/therapeutic use*
- From:
Journal of Zhejiang University. Medical sciences
2025;54(3):411-421
- CountryChina
- Language:Chinese
-
Abstract:
Retinopathy of prematurity (ROP) is a proliferative retinal vascular disease that threatens the vision of premature infants. Various novel drugs have demonstrated therapeutic potential for ROP by targeting signaling pathways associated with vascular endothelial growth factor (VEGF) [such as PI3K/AKT, hypoxia-inducible factor (HIF)-1α/VEGF], oxidative stress, tumor necrosis factor (TNF)-α, and Notch pathways. Propranolol, insulin-like growth factor-1, and celecoxib attenuate pathological neovascularization via the PI3K/Akt signaling pathway. Tripterine and melatonin inhibit retinal neovascularization by modulating the HIF-1α/VEGF signaling axis. Adiponectin mitigates the damage caused by oxidative stress and preserves endothelial function by enhancing endothelial nitric oxide synthase activity. Omega-3 polyunsaturated fatty acids suppress TNF-α-mediated inflammatory responses, modulate retinal development and angiogenesis, and reduce retinal neovascular lesions. DAPT, a γ-secretase inhibitor, blocks Notch signaling to suppress abnormal vascular proliferation. These agents exhibit synergistic multi-pathway anti-angiogenic effects in preclinical models and early-phase clinical trials, offering critical insights for advancing drug development and clinical translation in ROP management.
